Market Overview:
The global oral antidiabetic (OAD) treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising prevalence of diabetes, increasing awareness about diabetes and its complications, and technological advancements in the field of oral antidiabetics. Based on type, the sulphonylureas segment is expected to account for the largest share of the global oral antidiabetic (OAD) treatment market in 2018. This segment is also projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. Sulphonylureas are one of the oldest classes of drugs used for treating type 2 diabetes mellitus and are relatively inexpensive compared with other classes of drugs available for this indication. They work by stimulating insulin secretion from pancreatic beta cells, which helps lower blood glucose levels in patients with type 2 diabetes mellitus. Based on application, hospitals are expected to account for the largest share of the global oral antidiabetic (OAD) treatment market in 2018 followed by clinics and diabetics’ treatment centres respectively.
 Treatment Industry Outlook.svg)
Product Definition:
OADs are medications used to treat diabetes mellitus. They work by lowering blood sugar levels and can be taken orally or injected. OADs are important for managing diabetes because they help keep blood sugar levels under control, which can prevent or delay the onset of complications.
Sulphonylureas:
Sulphonylureas are used to treat type II diabetes and are categorized as antidiabetic drugs. They work by increasing the amount of insulin released by the body, which in turn reduces the amount of sugar (glucose) in the blood.
Biguanides:
Biguanides are a class of drug that works by increasing the sensitivity of cells to insulin. They were first introduced in the early sixties and have been used extensively ever since. The most common biguanide prescribed today is metformin, which is sold under various brand names worldwide including Glucophage, Riomet, and Sugar Free.
Application Insights:
The others segment held the largest share of over 50.0% in 2017. The other application includes metformin and sulfonylureas. Metformin is widely used for the treatment of type 2 diabetes as it reduces the blood glucose level by increasing insulin sensitivity, which improves metabolism and reduces body fat accumulation in obese patients with diabetes mellitus. However, metformin has a lower preference due to its side effects such as nausea, vomiting, diarrhea and abdominal pain which limits its usage rate across the globe.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region over the forecast period. The growth can be attributed to rising diabetic population, increasing awareness about OAD treatment options, and availability of effective OADs at low cost. Moreover, growing penetration of generics in this region will drive market growth further.
North America held a significant share in 2016 owing to high demand for generic drugs along with favorable reimbursement policies that have increased patient access to these therapies. In addition, presence of major players such as Novo Nordisk; Sanofi; Roche Diabetes Care Canada Inc.; and Takeda Pharmaceuticals Canada Inc.
Europe was estimated at USD X billion in 2016.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing at an alarming rate. This is mainly due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increase in the number of people who are susceptible to developing type 2 diabetes. This provides a major growth opportunity for oral antidiabetic drugs.
- Rising awareness about oral antidiabetic drugs: There is a growing awareness among people about the benefits and efficacy of oral antidiabetic drugs in controlling blood sugar levels in diabetics. This has led to an increase in their adoption rates worldwide.
- Technological advancements in oral antidiabetic drug delivery systems: Oral antidiabetic drug delivery systems are constantly evolving with new technological advancements being made regularly. This has helped improve the absorption and efficacy of these drugs, thus driving their growth prospects globally..
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Antidiabetic (OAD) Treatment Market Research Report
By Type
Sulphonylureas, Biguanides, Intestinal α-Glucosidase Inhibitors, Others
By Application
Hospital, Clinics, Diabetics Treatment Centres, Others
By Companies
Pfizer, Eli Lilly, Merck, Sanofi, AstraZeneca, Glenmark, Novartis, Boehringer Ingelheim, Novo Nordisk, Mannkind
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Oral Antidiabetic (OAD) Treatment Market Report Segments:
The global Oral Antidiabetic (OAD) Treatment market is segmented on the basis of:
Types
Sulphonylureas, Biguanides, Intestinal α-Glucosidase Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Diabetics Treatment Centres, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Eli Lilly
- Merck
- Sanofi
- AstraZeneca
- Glenmark
- Novartis
- Boehringer Ingelheim
- Novo Nordisk
- Mannkind
 Treatment Market Overview.svg)
Highlights of The Oral Antidiabetic (OAD) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sulphonylureas
- Biguanides
- Intestinal α-Glucosidase Inhibitors
- Others
- By Application:
- Hospital
- Clinics
- Diabetics Treatment Centres
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Antidiabetic (OAD) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral antidiabetic (OAD) treatment is a type of diabetes medication taken by mouth. It helps lower blood sugar levels by slowing the absorption of glucose from the intestine. OADs are often used in combination with other diabetes medications, such as insulin or oral hypoglycemic agents (OHAs).
Some of the key players operating in the oral antidiabetic (oad) treatment market are Pfizer, Eli Lilly, Merck, Sanofi, AstraZeneca, Glenmark, Novartis, Boehringer Ingelheim, Novo Nordisk, Mannkind.
The oral antidiabetic (oad) treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Antidiabetic (OAD) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Antidiabetic (OAD) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Antidiabetic (OAD) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Antidiabetic (OAD) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Antidiabetic (OAD) Treatment Market Size & Forecast, 2020-2028
4.5.1 Oral Antidiabetic (OAD) Treatment Market Size and Y-o-Y Growth
4.5.2 Oral Antidiabetic (OAD) Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Sulphonylureas
5.2.2 Biguanides
5.2.3 Intestinal α-Glucosidase Inhibitors
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Diabetics Treatment Centres
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Antidiabetic (OAD) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Antidiabetic (OAD) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Sulphonylureas
9.6.2 Biguanides
9.6.3 Intestinal α-Glucosidase Inhibitors
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinics
9.10.3 Diabetics Treatment Centres
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Sulphonylureas
10.6.2 Biguanides
10.6.3 Intestinal α-Glucosidase Inhibitors
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinics
10.10.3 Diabetics Treatment Centres
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Sulphonylureas
11.6.2 Biguanides
11.6.3 Intestinal α-Glucosidase Inhibitors
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinics
11.10.3 Diabetics Treatment Centres
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Sulphonylureas
12.6.2 Biguanides
12.6.3 Intestinal α-Glucosidase Inhibitors
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinics
12.10.3 Diabetics Treatment Centres
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Sulphonylureas
13.6.2 Biguanides
13.6.3 Intestinal α-Glucosidase Inhibitors
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinics
13.10.3 Diabetics Treatment Centres
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Antidiabetic (OAD) Treatment Market: Competitive Dashboard
14.2 Global Oral Antidiabetic (OAD) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Eli Lilly
14.3.3 Merck
14.3.4 Sanofi
14.3.5 AstraZeneca
14.3.6 Glenmark
14.3.7 Novartis
14.3.8 Boehringer Ingelheim
14.3.9 Novo Nordisk
14.3.10 Mannkind
